Trial Profile
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Study Evaluating the Efficacy and Safety of JTT-305 Administered for Six Months in Postmenopausal Women with Osteoporosis.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 Nov 2012
Price :
$35
*
At a glance
- Drugs Encaleret (Primary)
- Indications Postmenopausal osteoporosis
- Focus Therapeutic Use
- Sponsors Akros Pharma
- 16 Aug 2011 New trial record